Daniel Raftery

Daniel Raftery has developed NMR and mass spectrometry-based targeted metabolomics panels for cancer screening and diagnosis, achieving clinical validation for metabolic biomarker signatures in colorectal, breast, and pancreatic cancers. His multi-platform metabolomics approach combining NMR with mass spectrometry provides comprehensive metabolome coverage essential for discovering robust clinical biomarkers. His work on clinical validation of metabolomics-based cancer diagnostic tests has established the evidence standards for regulatory approval of metabolite biomarker assays.